The best approach in motorized Parkinson‘s disease therapy is APOMORPHINE INFUSION

Czech version

Published in: Cesk Slov Neurol N 2018; 81(5): 516
Category: Controversions

Sources

1. Hughes AJ, Daniel SE, Ben-Shlomo Y et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125(Pt 4): 861– 870.

2. Volkmann J, Albanese A, Antonini A et al. Select ing deep brain stimulation or infusion ther apies in advanced Parkinson’s dis ease: an evidence-based review. J Neurol 2013; 260(11): 2701– 2714.

3. García Ruiz PJ, Sesar Ignacio A, Ares-Pensado B et al. Efficacy of long term subcutaneous apomorphine infusion in advanced Parkinson’s dis ease with motor fluctuations: a multicenter study. Mov Disord 2008; 23(8): 1130– 1136.

4. Mensikova K, Kaiserova M, Vastik M et al. Treatment of camptocormia with continuous subcutaneous infusions of apomorphine: 1-year prospective pilot study. J Neural Transm 2015; 122(6): 835– 839.

5. Borgemeester RW, Lees AJ, van Laar T. Parkinson’s disease, visual hal lucinations and apomorphine: A review of the available evidence. Parkinsonism Relat Disord 2016; 27: 35– 40.

6. Borgemeester RW, van Laar T. Continuous subcutaneous apomorphine infusion in Parkinson’s dis ease patients with cognitive dysfunction: a retrospective longterm follow-up study. Parkinsonism Relat Disord 2017; 45:33– 38.

7. Yarnall AJ, Lashley T, L ing H et al. Apomorphine: a potential modifier of amyloid deposition in Parkinson’s disease? Mov Disord 2016; 31(5): 668– 675.